We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

BioFreedom FIM Clinical Trial.

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 29, 2010
Last Update Posted: September 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Biosensors Europe SA
July 28, 2010
July 29, 2010
September 9, 2014
August 2008
June 2010   (Final data collection date for primary outcome measure)
In-Stent Late Lumen Loss at 12 months post-procedure. [ Time Frame: 12 Months ]
Same as current
Complete list of historical versions of study NCT01172119 on ClinicalTrials.gov Archive Site
  • In-Stent Late Lumen Loss (LL) at 4 months post-procedure for patients receiving IVUS/Angio at 4 months [ Time Frame: 4 months ]
  • 2. Major adverse cardiac events (MACE) at 30 days, defined as death, myocardial infarction or ischemic target vessel revascularization (PCI or CABG). [ Time Frame: 30 days ]
  • 3. Major Adverse Cardiac Event (MACE) at hospital discharge, 30 days, 4 months, 12 months, and 2, 3, 4 and 5 years post-procedure. [ Time Frame: 5 years ]
  • Vascular complications through hospital discharge. [ Time Frame: 5 years ]
  • 5. Rates of stent thrombosis, per ARC definition of definite and probable and categorized as early, late or very late, at 30 days, 4 and 12 months, 2, 3, 4 and 5 years post-procedure. [ Time Frame: 5 years ]
  • 6. Biolimus A9 drug systemic drug levels post-procedure, 4 hours post-procedure, at hospital discharge, and at 30 days and 4 months clinical follow-up. [ Time Frame: 4 months ]
Same as current
Not Provided
Not Provided
BioFreedom FIM Clinical Trial.
A Prospective, Single Blinded, Randomized Study to Evaluate the Safety and Effictiveness of a Low and Standard Dose Biolimus A9TM Drug-Eluteing Coronary Stent Delivery System Compared With a TaxusTM LiberteTM Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries.
Prospective, multi center, randomized, single blinded study designed to demonstrate the safety and effectiveness of the Biosensors BioFreedom Drug-Eluting Coronary Stent Delivery System at multiple time points compared to the Taxus Liberte DES in the treatment of single de novo native coronary artery lesions ranging in diameter from ≥2.5 mm to ≤3.0 mm and ≤ 14 mm in length.
Not Provided
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Treatment Of Stenotic Lesions In Native Coronary Arteries.
  • Device: Biofreedom Drug Eluting Stent
    Biofreedom DES with a standard dose of Biolimus A9TM
  • Device: Biofreedom Drug Eluting Stent
    Biofreedom DES with a low dose of Biolimus A9TM
  • Device: Tuxus Liberte Drug Eluting Stent
    Standard paclitaxel dose Taxus Liberte DES
  • Experimental: BioFreedom Standard Dose
    Intervention: Device: Biofreedom Drug Eluting Stent
  • Experimental: BioFreedom Low Dose
    Intervention: Device: Biofreedom Drug Eluting Stent
  • Active Comparator: Taxus Liberte drug eluting stents
    Intervention: Device: Tuxus Liberte Drug Eluting Stent
Costa RA, Abizaid A, Mehran R, Schofer J, Schuler GC, Hauptmann KE, Magalhães MA, Parise H, Grube E; BioFreedom FIM Clinical Trial Investigators. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovasc Interv. 2016 Jan 11;9(1):51-64. doi: 10.1016/j.jcin.2015.09.008.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2014
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject is >18 years of age.
  • The subject is an acceptable candidate for PTCA, stenting, and emergent CABG.
  • Patients with multiple lesions as long as the last lesion to be treated fits the Inclusion criteria of the target lesion.
  • The subject must have clinical evidence of ischemic heart disease or a positive functional study.
  • The study stent target vessel must be a native coronary artery with a stenosis of >50% and <100%.
  • The study stent target vessel reference diameter must be >2.5 mm and ≤ 3.0 mm.(Measurements may be made by careful visual estimate or on-line quantitative coronary angiography.)
  • The study stent target lesion is a de novo lesion that has not been previously stented.
  • The study stent target lesion must be ≤ 14 mm in length thus allowing for adequate lesion coverage with a single stent.
  • The subject is male or, if female, is either not of childbearing potential or has had a negative pregnancy test within seven (7) days prior to the procedure.
  • The subject or the subject's legal representative has been informed of the nature of the study and has provided written informed consent as approved by the Institutional Ethics Committee (IEC) of the clinical site.
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria:

  • Multiple lesions to be treated in the same target vessel.
  • Patients who require more than one BioFreedom stent except that an additional BioFreedom stent may be implanted in the target lesion for geographic miss or bailout
  • A documented left ventricular ejection fraction < 30% assessed within 6 months prior to procedure by echocardiography, during a previous angiography or as measured during pre-procedure angiography.
  • A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticlopidine and, clopidogrel, stainless steel, Biolimus A9, Paclitaxel or a sensitivity to contrast media, which cannot be adequately pre-medicated.
  • A platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a WBC <3,000 cells/mm³.
  • Evidence of an acute myocardial infarction within 72 hours of the intended treatment (defined as: Q wave or non-Q wave infarction having CK enzymes > 2 times the upper laboratory normal with the presence of a CK-MB elevated above the institutions upper limit of normal).
  • A previous coronary interventional procedure was performed either a.) within 24 hours prior to the procedure or b.) within 12 months prior to the procedure for any lesion in the target vessel.
  • The subject requires planned interventional treatment of any lesion in either the target vessel within 12 months or in any non-target vessel within 30 days post-procedure.
  • The target and non-target lesion require treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
  • The target vessel has angiographic evidence of thrombus or is excessively (2 bends > 90º to reach the target lesion) tortuous.
  • The target lesion has any of the following characteristics:

    1. Lesion location is aorto-ostial, left main coronary artery, or within 5 mm of the origin of the LAD, LCX, or RCA.
    2. Is at a >45º bend in the vessel.
    3. Is moderately to severely calcified (visible by fluoro).
  • Stenting of the target or non-target lesion would "jail" or cover a side branch >2.0 mm in diameter or occur at the ostium of the sidebranch.
  • History of a stroke or transient ischemic attack (TIA) within the prior 6 months or permanent neurologic deficit.
  • History of upper GI bleeding within the prior 6 months.
  • The subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  • Concurrent medical condition with a life expectancy of less than 18 months.
  • Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.]
  • Any contraindications as mentioned in the TaxusTM LiberteTM Instructions for Use (IFU).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Biosensors Europe SA
Biosensors Europe SA
Not Provided
Principal Investigator: Eberhard Grube, Prof Dr med Department of Cardiology Hospital Alemao O. Cruz, Sao Paulo, Brazil
Biosensors Europe SA
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP